Literature DB >> 24434782

Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Jeffrey W Leong1, Julie M Chase1, Rizwan Romee1, Stephanie E Schneider1, Ryan P Sullivan1, Megan A Cooper2, Todd A Fehniger3.   

Abstract

Natural killer (NK) cells are effector lymphocytes that are under clinical investigation for the adoptive immunotherapy of hematologic malignancies, especially acute myeloid leukemia. Recent work in mice has identified innate memory-like properties of NK cells. Human NK cells also exhibit memory-like properties, and cytokine-induced memory-like (CIML) NK cells are generated via brief preactivation with IL-12, IL-15, and IL-18, which later exhibit enhanced functionality upon restimulation. However, the optimal cytokine receptors and signals for maintenance of enhanced function and homeostasis after preactivation remain unclear. Here, we show that IL-12, IL-15, and IL-18 preactivation induces a rapid and prolonged expression of CD25, resulting in a functional high-affinity IL-2 receptor (IL-2Rαβγ) that confers responsiveness to picomolar concentrations of IL-2. The expression of CD25 correlated with STAT5 phosphorylation in response to picomolar concentrations of IL-2, indicating the presence of a signal-competent IL-2Rαβγ. Furthermore, picomolar concentrations of IL-2 acted synergistically with IL-12 to costimulate IFN-γ production by preactivated NK cells, an effect that was CD25 dependent. Picomolar concentrations of IL-2 also enhanced NK cell proliferation and cytotoxicity via the IL-2Rαβγ. Further, after adoptive transfer into immunodeficient NOD-SCID-γc(-/-) mice, human cytokine-preactivated NK cells expand preferentially in response to exogenous IL-2. Collectively, these data demonstrate that human CIML NK cells respond to IL-2 via IL-2Rαβγ with enhanced survival and functionality, and they provide additional rationale for immunotherapeutic strategies that include brief cytokine preactivation before adoptive NK cell transfer, followed by low-dose IL-2 therapy.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adoptive immunotherapy; Cytokine; IL-2; IL-2 receptor; NK cell

Mesh:

Substances:

Year:  2014        PMID: 24434782      PMCID: PMC3959288          DOI: 10.1016/j.bbmt.2014.01.006

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  49 in total

1.  Cytokine-induced memory-like natural killer cells.

Authors:  Megan A Cooper; Julie M Elliott; Peter A Keyel; Liping Yang; Javier A Carrero; Wayne M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-30       Impact factor: 11.205

Review 2.  Hidden talents of natural killers: NK cells in innate and adaptive immunity.

Authors:  Megan A Cooper; Marco Colonna; Wayne M Yokoyama
Journal:  EMBO Rep       Date:  2009-09-04       Impact factor: 8.807

Review 3.  Functions of natural killer cells.

Authors:  Eric Vivier; Elena Tomasello; Myriam Baratin; Thierry Walzer; Sophie Ugolini
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 4.  Natural killer cells: diversity in search of a niche.

Authors:  James P Di Santo
Journal:  Nat Immunol       Date:  2008-05       Impact factor: 25.606

Review 5.  Formation and function of the lytic NK-cell immunological synapse.

Authors:  Jordan S Orange
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

Review 6.  The biology of interleukin-2.

Authors:  Thomas R Malek
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

7.  Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Elizabeth Trachtenberg; Tracy L Bergemann; Koy Saeteurn; John Klein; Chap T Le; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller; Daniel J Weisdorf
Journal:  Blood       Date:  2008-10-22       Impact factor: 22.113

Review 8.  Human natural killer cells.

Authors:  Michael A Caligiuri
Journal:  Blood       Date:  2008-08-01       Impact factor: 22.113

9.  A programmed switch from IL-15- to IL-2-dependent activation in human NK cells.

Authors:  Anne-Hélène Pillet; Florence Bugault; Jacques Thèze; Lisa A Chakrabarti; Thierry Rose
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

10.  Adaptive immune features of natural killer cells.

Authors:  Joseph C Sun; Joshua N Beilke; Lewis L Lanier
Journal:  Nature       Date:  2009-01-11       Impact factor: 49.962

View more
  101 in total

1.  The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.

Authors:  Maximillian Rosario; Bai Liu; Lin Kong; Lynne I Collins; Stephanie E Schneider; Xiaoyue Chen; Kaiping Han; Emily K Jeng; Peter R Rhode; Jeffrey W Leong; Timothy Schappe; Brea A Jewell; Catherine R Keppel; Keval Shah; Brian Hess; Rizwan Romee; David R Piwnica-Worms; Amanda F Cashen; Nancy L Bartlett; Hing C Wong; Todd A Fehniger
Journal:  Clin Cancer Res       Date:  2015-09-30       Impact factor: 12.531

Review 2.  Natural killer cell memory in infection, inflammation and cancer.

Authors:  Adelheid Cerwenka; Lewis L Lanier
Journal:  Nat Rev Immunol       Date:  2016-01-25       Impact factor: 53.106

3.  Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Authors:  Elizabeth L McMichael; Nicholas B Courtney; Megan C Duggan; Robert Wesolowski; Dionisia Quiroga; Sri Vidya Kondadasula; Lakhvir S Atwal; Neela Bhave; Eric Luedke; Alena Cristina Jaime-Ramirez; Amanda R Campbell; Xiaokui Mo; John C Byrd; William E Carson Iii
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

4.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

5.  Influenza Vaccination Primes Human Myeloid Cell Cytokine Secretion and NK Cell Function.

Authors:  Helen R Wagstaffe; Harry Pickering; Joanna Houghton; Jason P Mooney; Asia-Sophia Wolf; Natalie Prevatt; Ron H Behrens; Martin J Holland; Eleanor M Riley; Martin R Goodier
Journal:  J Immunol       Date:  2019-08-19       Impact factor: 5.422

6.  Co-stimulation of the fc receptor and interleukin-12 receptor on human natural killer cells leads to increased expression of cd25.

Authors:  Megan C Duggan; Amanda R Campbell; Elizabeth L McMichael; Kallan S Opheim; Kala M Levine; Neela Bhave; Michelle C Culbertson; Tiffany Noel; Lianbo Yu; W E Carson
Journal:  Oncoimmunology       Date:  2017-10-16       Impact factor: 8.110

7.  Comparative study of different procedures for the separation of peripheral blood mononuclear cells in cytokine-induced killer cell immunotherapy for hepatocarcinoma.

Authors:  Hui Liu; Jianyu Li; Fengmei Wang; Yingtang Gao; Ying Luo; Peng Wang; Chenglong Li; Zhengyan Zhu
Journal:  Tumour Biol       Date:  2014-11-24

8.  IL15 induces a potent antitumor activity in NK cells isolated from malignant pleural effusions and overcomes the inhibitory effect of pleural fluid.

Authors:  D Croxatto; S Martini; L Chiossone; F Scordamaglia; C F Simonassi; L Moretta; M C Mingari; P Vacca
Journal:  Oncoimmunology       Date:  2017-02-17       Impact factor: 8.110

Review 9.  Engineering Natural Killer Cells for Cancer Immunotherapy.

Authors:  Katayoun Rezvani; Rayne Rouce; Enli Liu; Elizabeth Shpall
Journal:  Mol Ther       Date:  2017-06-28       Impact factor: 11.454

10.  Adoptively transferred natural killer cells maintain long-term antitumor activity by epigenetic imprinting and CD4+ T cell help.

Authors:  Jing Ni; Oliver Hölsken; Matthias Miller; Quirin Hammer; Merlin Luetke-Eversloh; Chiara Romagnani; Adelheid Cerwenka
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.